Palatin Technologies (NYSEAMERICAN:PTN) Stock Price Down 13.5% – What’s Next?

Palatin Technologies (NYSEAMERICAN:PTN) fell 13.5% on Wednesday . The company traded as low as $9.42 and last traded at $9.46. Approximately 137,449 shares were traded during trading, an increase of 289% from the average daily volume of 35,362 shares. The stock had previously closed at $10.94.

Palatin Technologies Stock Up 3.7%

The company has a fifty day simple moving average of $9.74 and a 200-day simple moving average of $14.51.

Institutional Trading of Palatin Technologies

A hedge fund recently bought a new position in Palatin Technologies stock. Opaleye Management Inc. purchased a new position in shares of Palatin Technologies (NYSEAMERICAN:PTN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 20,500 shares of the company’s stock, valued at approximately $221,000. Opaleye Management Inc. owned 1.15% of Palatin Technologies at the end of the most recent quarter. Institutional investors own 11.50% of the company’s stock.

About Palatin Technologies

Palatin Technologies, Inc is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, a group of receptors involved in regulating sexual function, inflammation, metabolism and other biological processes. The company’s approach uses synthetic peptide therapeutics designed to selectively activate or modulate these receptors.

Palatin’s most advanced product is Vyleesi (bremelanotide), an injectable melanocortin receptor agonist approved in the United States for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.